|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 1 January 2007, Vol. 109, No. 1, pp. 8.
JAK2V617F and phenotype: questions galoreMAYO CLINIC
The JAK2V617F mutation is associated with a range of hematologic disorders. Xu and colleagues find a surprisingly high prevalence of JAK2V617F in a large cohort of unselected patients.
The increasingly wider availability of JAK2V617F assays and their use in newer clinical settings suggests that the phenotypic limits of the mutation have not yet been defined. Indeed, use of allele-specific polymerase chain reaction (AS-PCR) for JAK2V617F detection where the assay sensitivity approaches 0.01% has recently identified a very low mutation level in the blood of up to 10% of healthy volunteers in one study.1 In this issue of Blood, Xu and colleagues report a relatively high JAK2V617F prevalence (approximately 1%) using AS-PCR (sensitivity limit of 0.25%) in their analysis of 3935 blood samples collected at a single Chinese hospital over 6 months. Both studies reveal a surprisingly high frequency of JAK2V617F than would be predicted from estimates of myeloproliferative disorder (MPD) prevalence in the respective populations studied. These findings are intriguing, yet confounding, and raise many questions regarding the phenotypic correlates of JAK2V617F: first, can the findings be extrapolated to other populations? Indeed not as of now, it seems, given the failure to detect JAK2V617F in healthy controls screened by comparably sensitive assays in other studies.2 Also, the specific population to which the current findings of Xu and colleagues is applicable is difficult to ascertain given the paucity of clinical data provided for their JAK2V617F-positive patients. In considering patient blood counts, while nearly a third exhibited some degree of leukocytosis and/or thrombocytosis, these findings may be secondary or reactive, as would be commonly expected in a hospital population, and consequently, this cannot be taken as unequivocal evidence for early-stage MPD. Second, is acquisition of JAK2V617F sufficient per se for MPD development? While these findings, if confirmed, suggest that JAK2V617F is an early genetic event, they do not directly address this question. Expression of a particular MPD phenotype (say, PV) reflects time-dependent events, including progressive JAK2V617F clonal dominance, accompanied in some cases by transition from JAK2V617F heterozygosity to homozygosity through mitotic recombination,3 and potential acquisition of additional genetic "hits" (eg, JAK2D620E or MPLW515L/K)4 that may bias clinical disease expression. Last, does detection of JAK2V617F by highly sensitive molecular assays indicate a "form fruste" of MPD in certain situations (eg, idiopathic thrombosis) where accepted diagnostic criteria for MPD are not fulfilled? While presently unknown, this is likely to be an area of intense interest that examines the contributions of JAK2V617F gene dosage, zygosity, and clonal burden, as well as their interactions with other genetic and/or environmental factors (eg, inherited thrombophilias) toward expression of a particular clinical phenotype.
Footnotes
The author declares no competing financial interests.
References
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2007 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
